Maximum androgen blockade
Maximum or maximal androgen blockade (MAB) or complete or combined androgen blockade (CAB) is a medical treatment involving the combination of both androgen receptor (AR) antagonism and inhibition or suppression of androgen production to attain maximal effectiveness in androgen deprivation therapy (ADT).[1] An example of MAB is the combination of bicalutamide, an AR antagonist, with a gonadotropin-releasing hormone (GnRH) analogue such as leuprorelin or cetrorelix.[1] MAB was developed for and is employed in the treatment of prostate cancer.[1]
Triple androgen blockade (TrAB) is a method of ADT in which a 5α-reductase inhibitor such as finasteride or dutasteride is added to CAB.[2][3]
References
- 1 2 3 "Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials". The Lancet. 355 (9214): 1491–1498. 2000. doi:10.1016/S0140-6736(00)02163-2. ISSN 0140-6736.
- ↑ Hellerstedt, Beth A; Pienta, Kenneth J (2003). "The truth is out there: an overall perspective on androgen deprivation". Urologic Oncology: Seminars and Original Investigations. 21 (4): 272–281. doi:10.1016/S1078-1439(03)00046-2. ISSN 1078-1439.
- ↑ Leibowitz RL, Tucker SJ (2001). "Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients". The Oncologist. 6 (2): 177–82. PMID 11306729.
| AR |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||||||
See also: Estrogenics • Glucocorticoidics • Mineralocorticoidics • Progestogenics • Steroid hormone metabolism modulators • List of androgens/anabolic steroids | |||||||||||
This article is issued from Wikipedia - version of the 10/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.